GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2008

PharmAthene Retains GTC’s Manufacturing Services for Protexia

  • GTC Biotherapeutics will continue to conduct process development and clinical manufacturing services for PharmAthene’s Protexia® program. The manufacturing work is planned to conclude in the third quarter.

    Protexia is being developed as a pre- and postexposure therapy for victims of a chemical nerve agent attack. It is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?